Morgan Stanley
SION

Morgan Stanley’s Sionna Therapeutics SION Stock Holding History

Morgan Stanley’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.33M Buy
133,023
+83,147
+167% +$3.17M ﹤0.01% 4087
2025
Q4 		$2.05M Buy
49,876
+27,039
+118% +$1.03M ﹤0.01% 4793
2025
Q3 		$672K Sell
22,837
-21,181
-48% -$461K ﹤0.01% 5368
2025
Q2 		$764K Buy
44,018
+40,079
+1,017% +$525K ﹤0.01% 5244
2025
Q1 		$41.2K Buy
+3,939
New +$64.4K ﹤0.01% 6336

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley's SION Position: Q1 2026 in Review

Morgan Stanley increased its Sionna Therapeutics (SION) stake by 167% in Q1 2026, buying an estimated $3.17M and bringing the position to 133,023 shares worth $5.33M. The position accounts for ﹤0.01% of the portfolio, ranked #4087.

Morgan Stanley first reported a position in SION in Q1 2025 and has held it in 5 quarters since. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • Morgan Stanley held 133,023 shares of Sionna Therapeutics worth $5.33M as of Q1 2026.
  • Morgan Stanley bought 83,147 Sionna Therapeutics shares in Q1 2026, an estimated $3.17M.
  • Sionna Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4087 holding.
  • Morgan Stanley first reported a position in Sionna Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.